Kathleen Shannon-Dorcy

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

SummaryIn a blinded retrospective economic evaluation of a double-blind, randomised. placebo-controlled clinical trial, total utilisation and charges for lymphoid cancer patients who received recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) or placebo were compared following autologous bone marrow transplantation. The 40 patients enrolled (22 rhGM-CSF, 18 placebo) could have acute lymphoblastic leukaemia, non-Hodgkins lymphoma or Hodgkin’s disease, be of any age, and were undergoing autologous bone marrow transplantation in a metropolitan cancer research centre. Main outcome measures consisted of initial hospital lengths of stay (LOS). total and department charges. rehospitalisation rates and charges. and outpatient charges. all inclusive of the first 100 days following bone marrow infusion. The perspective of the study is that of the third party payer.Initial hospitalisation charges were

Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study

US54 100 fo r patients who received rhGM-CSF and

Value of routine ‘day 14’ marrow exam in newly diagnosed AML

US68 600 for patients who received placebo (p = 0.05). The difference of

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

US14 500 was 21% less in patients who received rhGM-CSF. mainly due to lower average LOS with rhGM-CSF (24.2 days) compared with placebo (30.8 days). Outpatient charges were

Decision-making in the diagnosis and treatment of leukemia

US9500 (rhGM-CSF) and

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

US6800 (placebo) [p = 0.18]. Total charges, including readmission (10 per group) were

Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor

USI2 200 lower in the rhGM-CSF group (

Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation.

US70 300 vs

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

US82 500, P = 0.19).The use of rhGM-CSF after autologous bone marrow transplantation was shown to result in substantial cost savings during the initial hospitalisation. When comparing total inpatient and outpatient medical charges within the first 100 days following bone marrow infusion, we found no evidence that these savings were negated.

Follow-up of Related Stem Cell Donors One Week Post Donation

Due to infectious and bleeding risks, adults with acute myeloid leukemia or high-risk myelodysplastic syndromes typically remain hospitalized after remission induction chemotherapy until blood count recovery. Here, we explored the medical and financial effects of discharge immediately after chemotherapy completion with close outpatient follow up. Within 12 months, 15 patients fulfilling both medical and logistical criteria were discharged early, whereas 5 patients meeting medical criteria only served as inpatient controls. No patient died. Patients discharged early spent a median of 8 days (range 3–36 days), or 54% of their study time, as outpatients. These patients required less time on intravenous antibiotics (6 vs. 16 days; P=0.11), received fewer red blood cell transfusions (0.25 vs. 0.48 units/day; P=0.08), and incurred lower median daily charges (